Teva reports positive results for fremanezumab in phase IIIb migraine trial

Teva Pharmaceutical Industries said that the phase IIIb FOCUS study that evaluated the efficacy and safety of fremanezumab for the preventive treatment of migraine in adult patients has yielded positive results.